carveratio 25 mg tabletti
ratiopharm gmbh - carvedilol - tabletti - 25 mg - karvediloli
tysabri
biogen netherlands b.v. - natalitsumabin - multippeliskleroosi - selektiiviset immunosuppressantit - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 ja 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
fml liquifilm 1 mg/ml silmätipat, suspensio
abbvie oy - fluorometholone - silmätipat, suspensio - 1 mg/ml - fluorometoloni
pred forte 10 mg/ml silmätipat, suspensio
abbvie oy - prednisolone acetate - silmätipat, suspensio - 10 mg/ml - prednisoloni
alphagan 0,2 % (2 mg/ml) silmätipat, liuos
abbvie oy - brimonidine tartrate - silmätipat, liuos - 0,2 % (2 mg/ml) - brimonidiini
mydriasert 0.28 mg / 5.4 mg silmälamelli
laboratoires thea - phenylephrine hydrochloride, tropicamide - silmälamelli - 0.28 mg / 5.4 mg - tropikamidi
oftastad 50 mikrog/ml silmätipat, liuos
stada arzneimittel ag - latanoprost - silmätipat, liuos - 50 mikrog/ml - latanoprosti
rasagiline accord 1 mg tabletti
accord healthcare b.v. - rasagiline tartrate - tabletti - 1 mg - rasagiliini
lencya 30 mg tabletti, kalvopäällysteinen
sandoz a/s sandoz a/s - ulipristali acetas - tabletti, kalvopäällysteinen - 30 mg - ulipristaali
tenoblock 100 mg tabletti
takeda oy takeda oy - atenololum - tabletti - 100 mg - atenololi